Edesa Biotech (EDSA) Stock Analysis

What Edesa Biotech does

Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.

Key metrics

ETFs linked to EDSA

Broad-market and Healthcare sector ETFs an investor holding Edesa Biotech is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how EDSA fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Edesa Biotech?

Edesa Biotech trades under the ticker EDSA on NASDAQ.

Which exchange is EDSA listed on?

EDSA is listed on NASDAQ.

What sector does Edesa Biotech operate in?

Edesa Biotech is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze EDSA in a portfolio?

PortView shows EDSA's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.